In this episode, Joe Moore interviews the Co-Founders of Tesselate Therapeutics: Dr. Rochelle Hines, Ph.D. (also the CEO and an Associate Professor at UNLV), and Dr. Dustin Hines, Ph.D. (the CSO as well as an Assistant Professor at UNLV). While Tesselate’s primary objective is the development of novel psychedelic molecules, the Hines’ work goes much deeper than that, as they are researching the ways the brain communicates with itself and other parts of the body: how neurotransmitter systems interact, why synaptic partners find each other, and how certain substances may be able to modulate the actions of specific receptors. They talk about the reductionist base of neuroscience; the biodiversity in human populations and how heterogeneous depression can be; the structure of the cerebral cortex; neuroplasticity; the price of bringing new drugs to the FDA and the strategy of “failing fast,” and much more.

The post PT366 – Neurotransmitter Systems and Novel Psychedelic Molecules appeared first on Psychedelics Today.

Previous articleatai Life Sciences Announces R&D Day Agenda
Next articleSilo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study